Literature DB >> 18559970

Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.

Victor-F Mautner1, Florence A Asuagbor, Eva Dombi, Carsten Fünsterer, Lan Kluwe, Ralf Wenzel, Brigitte C Widemann, Jan M Friedman.   

Abstract

People with neurofibromatosis 1 (NF1) have multiple benign neurofibromas and a 10% lifetime risk of developing malignant peripheral nerve sheath tumors (MPNSTs). Most MPNSTs develop from benign plexiform neurofibromas, so the burden of benign tumors may be a risk factor for developing MPNST. We studied 13 NF1 patients with MPNSTs and 26 age- and sex-matched controls (NF1 patients who did not have MPNSTs) with detailed clinical examinations and whole-body MRI to characterize their body burden of internal benign neurofibromas. Internal plexiform neurofibromas were identified in 22 (56%) of the 39 NF1 patients studied. All six of the NF1 patients with MPNSTs under 30 years of age had neurofibromas visualized on whole-body MRI, compared to only 3 of 11 matched NF1 controls under age 30 (p < 0.05). Both the median number of plexiform neurofibromas (p < 0.05) and the median neurofibroma volume (p < 0.01) on whole-body MRI were significantly greater among MPNST patients younger than 30 years of age than among controls. No significant differences in whole-body MRI findings were observed between NF1 patients with MPNSTs and controls who were 30 years of age or older. Whole-body MRI of NF1 patients allows assessment of the burden of internal neurofibromas, most of which are not apparent on physical examination. Whole-body imaging of young NF1 patients may allow those at highest risk for developing MPNST to be identified early in life. Close surveillance of these high-risk patients may permit earlier diagnosis and more effective treatment of MPNSTs that develop.

Entities:  

Mesh:

Year:  2008        PMID: 18559970      PMCID: PMC2666233          DOI: 10.1215/15228517-2008-011

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  38 in total

Review 1.  Clinical features and pathobiology of neurofibromatosis 1.

Authors:  Bruce R Korf
Journal:  J Child Neurol       Date:  2002-08       Impact factor: 1.987

Review 2.  Genetics of neurofibromatosis 1 and the NF1 gene.

Authors:  David Viskochil
Journal:  J Child Neurol       Date:  2002-08       Impact factor: 1.987

3.  Evaluation of (18)fluorodeoxyglucose positron emission tomography ((18)FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1.

Authors:  R E Ferner; J D Lucas; M J O'Doherty; R A Hughes; M A Smith; B F Cronin; J Bingham
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-03       Impact factor: 10.154

4.  Elevated risk for MPNST in NF1 microdeletion patients.

Authors:  T De Raedt; H Brems; P Wolkenstein; D Vidaud; S Pilotti; F Perrone; V Mautner; S Frahm; R Sciot; E Legius
Journal:  Am J Hum Genet       Date:  2003-03-26       Impact factor: 11.025

5.  Malignant peripheral nerve sheath tumours in neurofibromatosis 1.

Authors:  D G R Evans; M E Baser; J McGaughran; S Sharif; E Howard; A Moran
Journal:  J Med Genet       Date:  2002-05       Impact factor: 6.318

6.  Constitutional NF1 mutations in neurofibromatosis 1 patients with malignant peripheral nerve sheath tumors.

Authors:  Lan Kluwe; Reinhard E Friedrich; Matthias Peiper; Jan Friedman; Victor-F Mautner
Journal:  Hum Mutat       Date:  2003-11       Impact factor: 4.878

7.  High frequency of mosaicism among patients with neurofibromatosis type 1 (NF1) with microdeletions caused by somatic recombination of the JJAZ1 gene.

Authors:  H Kehrer-Sawatzki; L Kluwe; C Sandig; M Kohn; K Wimmer; U Krammer; A Peyrl; D E Jenne; I Hansmann; V-F Mautner
Journal:  Am J Hum Genet       Date:  2004-07-15       Impact factor: 11.025

8.  Neurofibromatosis 1-associated neuropathies: a reappraisal.

Authors:  Alain Drouet; Pierre Wolkenstein; Jean-Pascal Lefaucheur; Stéphane Pinson; Patrick Combemale; Romain K Gherardi; Pierre Brugières; Jeffrey Salama; Pascal Ehre; Philippe Decq; Alain Créange
Journal:  Brain       Date:  2004-08-02       Impact factor: 13.501

9.  Update on biologic behavior and surgical implications of neurofibromatosis and neurofibrosarcoma.

Authors:  R L Dales; V W McEver; G Quispe; R S Davies
Journal:  Surg Gynecol Obstet       Date:  1983-05

10.  Screening 500 unselected neurofibromatosis 1 patients for deletions of the NF1 gene.

Authors:  Lan Kluwe; Reiner Siebert; Stefan Gesk; Reinhard E Friedrich; Sigrid Tinschert; Hildegard Kehrer-Sawatzki; Victor-F Mautner
Journal:  Hum Mutat       Date:  2004-02       Impact factor: 4.878

View more
  72 in total

1.  Whole-body MRI in neurofibromatosis: incidental findings and prevalence of scoliosis.

Authors:  Jacob L Jaremko; Peter J MacMahon; Martin Torriani; Vanessa L Merker; Victor F Mautner; Scott R Plotkin; Miriam A Bredella
Journal:  Skeletal Radiol       Date:  2011-12-07       Impact factor: 2.199

Review 2.  Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.

Authors:  Brigitte C Widemann
Journal:  Curr Oncol Rep       Date:  2009-07       Impact factor: 5.075

3.  The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors.

Authors:  Christine S Higham; Eva Dombi; Aljosja Rogiers; Sucharita Bhaumik; Steven Pans; Steve E J Connor; Markku Miettinen; Raf Sciot; Roberto Tirabosco; Hilde Brems; Andrea Baldwin; Eric Legius; Brigitte C Widemann; Rosalie E Ferner
Journal:  Neuro Oncol       Date:  2018-05-18       Impact factor: 12.300

4.  Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.

Authors:  Michael J Fisher; Chie-Schin Shih; Steven D Rhodes; Amy E Armstrong; Pamela L Wolters; Eva Dombi; Chi Zhang; Steven P Angus; Gary L Johnson; Roger J Packer; Jeffrey C Allen; Nicole J Ullrich; Stewart Goldman; David H Gutmann; Scott R Plotkin; Tena Rosser; Kent A Robertson; Brigitte C Widemann; Abbi E Smith; Waylan K Bessler; Yongzheng He; Su-Jung Park; Julie A Mund; Li Jiang; Khadijeh Bijangi-Vishehsaraei; Coretta Thomas Robinson; Gary R Cutter; Bruce R Korf; Jaishri O Blakeley; D Wade Clapp
Journal:  Nat Med       Date:  2021-01-13       Impact factor: 53.440

Review 5.  Magnetic resonance imaging of the pediatric mediastinum.

Authors:  Dianna M E Bardo; Deepa R Biyyam; Mittun C Patel; Kevin Wong; Dane van Tassel; Ryan K Robison
Journal:  Pediatr Radiol       Date:  2018-08-04

6.  The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas.

Authors:  A Pemov; H Li; R Patidar; N F Hansen; S Sindiri; S W Hartley; J S Wei; A Elkahloun; S C Chandrasekharappa; J F Boland; S Bass; J C Mullikin; J Khan; B C Widemann; M R Wallace; D R Stewart
Journal:  Oncogene       Date:  2017-01-09       Impact factor: 9.867

Review 7.  Cancer of the Peripheral Nerve in Neurofibromatosis Type 1.

Authors:  Verena Staedtke; Ren-Yuan Bai; Jaishri O'Neill Blakeley
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

Review 8.  Whole-body magnetic resonance imaging in children: technique and clinical applications.

Authors:  Eric P Eutsler; Geetika Khanna
Journal:  Pediatr Radiol       Date:  2016-05-26

Review 9.  Spinal manifestations of Neurofibromatosis type 1.

Authors:  Ben Shofty; Ori Barzilai; Morsi Khashan; Zvi Lidar; Shlomi Constantini
Journal:  Childs Nerv Syst       Date:  2020-06-20       Impact factor: 1.475

10.  Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial.

Authors:  Kent A Robertson; Grzegorz Nalepa; Feng-Chun Yang; Daniel C Bowers; Chang Y Ho; Gary D Hutchins; James M Croop; Terry A Vik; Scott C Denne; Luis F Parada; Cynthia M Hingtgen; Laurence E Walsh; Menggang Yu; Kamnesh R Pradhan; Mary K Edwards-Brown; Mervyn D Cohen; James W Fletcher; Jeffrey B Travers; Karl W Staser; Melissa W Lee; Marcie R Sherman; Cynthia J Davis; Lucy C Miller; David A Ingram; D Wade Clapp
Journal:  Lancet Oncol       Date:  2012-10-23       Impact factor: 41.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.